Sorrento Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Revenues
Grant
Royalties and licenses
Sales and services
Product
Service
Total revenues

Operating costs and expenses:
Cost of product sold and services
Product
Service
Total cost of product sold and services

Research and development
Acquired in-process research and development
Selling, general and administrative
Intangible amortization
Loss (gain) on contingent liabilities
(Decrease) increase on contingent consideration
Loss on impairment of intangible assets
Legal settlements, net
Total operating costs and expenses

Loss from operations
Gain (loss) on derivative liabilities
Gain on marketable securities
Loss on marketable and equity investments
Gain (loss) on debt extinguishment
Loss on receivable
(Loss) gain on foreign currency exchange
Scilex Notes principal increase
Interest expense, net
Interest income
Other income (loss)
Loss before income tax
Income tax benefit
Loss on equity method investments
Net loss
Net loss attributable to noncontrolling interests
Net loss attributable to Sorrento
Net loss per share - basic per share attributable to Sorrento
Net loss per share - diluted per share attributable to Sorrento
Weighted-average shares outstanding during period - basic shares attributable to Sorrento (in shares)
Weighted-average shares outstanding during period - diluted shares attributable to Sorrento (in shares)

Comments